共 84 条
[1]
Galicia-Garcia U., Benito-Vicente A., Jebari S., Larrea-Sebal A., Siddiqi H., Uribe K.B., Ostolaza H., Martin C., Pathophysiology of type 2 diabetes mellitus, Int. J. Mol. Sci, 21, (2020)
[2]
Zatterale F., Longo M., Naderi J., Raciti G.A., Desiderio A., Miele C., Beguinot F., Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes, Front. Physiol, 10, (2020)
[3]
Mohammedi K., Chalmers J., Herrington W., Li Q., Mancia G., Marre M., Poulter N., Rodgers A., Williams B., Perkovic V., Et al., Associations between body mass index and the risk of renal events in patients with type 2 diabetes, Nutr. Diabetes, 8, (2018)
[4]
Kanwar Y.S., Sun L., Xie P., Liu F.Y., Chen S., A glimpse of various pathogenetic mechanisms of diabetic nephropathy, Annu. Rev. Pathol, 6, pp. 395-423, (2011)
[5]
Song A., Zhang C., Meng X., Mechanism and application of metformin in kidney diseases: An update, Biomed. Pharmacother, 138, (2021)
[6]
Wang H.H., Lin S.H., Hung S.Y., Chiou Y.Y., Hsu W.C., Chang C.M., Liou H.H., Chang M.Y., Ho L.C., Wu C.F., Et al., Renal protective effect of metformin in type 2 diabetes patients, J. Clin. Endocrinol. Metab, (2024)
[7]
Kwon S., Kim Y.C., Park J.Y., Lee J., An J.N., Kim C.T., Oh S., Park S., Kim D.K., Oh Y.K., Et al., The long-term effects of metformin on patients with type 2 diabetic kidney disease, Diabetes Care, 43, pp. 948-955, (2020)
[8]
Pan Q., Lu X., Zhao C., Liao S., Chen X., Guo F., Yang C., Liu H.F., Metformin: The updated protective property in kidney disease, Aging, 12, pp. 8742-8759, (2020)
[9]
Wu M., Xu H., Liu J., Tan X., Wan S., Guo M., Long Y., Xu Y., Metformin and fibrosis: A review of existing evidence and mechanisms, J. Diabetes Res, 2021, (2021)
[10]
Agarwal R., Pathogenesis of diabetic nephropathy, Chronic Kidney Disease and Type 2 Diabetes, (2021)